Terry J. Rosen Buys 19,800 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry J. Rosen bought 19,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $10.18 per share, with a total value of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $10.89 on Friday. Arcus Biosciences, Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $20.00. The business has a 50-day moving average of $13.37 and a two-hundred day moving average of $15.40. The stock has a market capitalization of $1.14 billion, a P/E ratio of -3.46 and a beta of 0.84. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to analysts’ expectations of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. On average, equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

RCUS has been the subject of a number of research reports. Bank of America reduced their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Morgan Stanley reduced their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Wedbush reissued an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $18.00 to $24.00 in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences has a consensus rating of “Buy” and an average target price of $30.25.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors have recently made changes to their positions in the business. Woodline Partners LP increased its stake in shares of Arcus Biosciences by 1.3% in the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company’s stock worth $52,471,000 after purchasing an additional 45,497 shares during the period. Two Sigma Advisers LP increased its stake in shares of Arcus Biosciences by 35.8% in the fourth quarter. Two Sigma Advisers LP now owns 58,800 shares of the company’s stock worth $876,000 after purchasing an additional 15,500 shares during the period. Two Sigma Investments LP increased its stake in shares of Arcus Biosciences by 8.1% in the fourth quarter. Two Sigma Investments LP now owns 146,686 shares of the company’s stock worth $2,184,000 after purchasing an additional 11,027 shares during the period. Tema Etfs LLC bought a new position in shares of Arcus Biosciences in the fourth quarter worth about $331,000. Finally, ProShare Advisors LLC increased its stake in shares of Arcus Biosciences by 44.4% in the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company’s stock worth $244,000 after purchasing an additional 5,038 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.